Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2023-10-20 00:00:00 ET · period of report 2023-10-19 · accession 0001415889-23-014454 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-10-20 | 2023-10-19 | PLX | Bashan Dror | Pres AND CEO, Dir | P - Purchase | $1.40 | +64.5K | 116.4K | +124% | +$90.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-19 | P | A | 16,129 | $1.41 | 132,516 | D | — | — | |
| 2 | Common | Common Stock | 2023-10-19 | P | A | 48,387 | $1.40 | 116,387 | D | — | — |